文献速递神经肿瘤神经重症

前庭神经鞘瘤立体定向放射外科治疗后脑室扩大与症状性交通性脑积水的风险

Risks associated with ventriculomegaly and symptomatic communicating hydrocephalus following stereotactic radiosurgery for vestibular schwannoma.
PubMed 文献 · J Neurosurg · 2026-05-01

结果显示SRS后脑室扩大发生率为3.6%,其中60.9%需脑室腹腔分流,中位分流时间8个月;荟萃分析总脑积水发生率为5%,症状性需分流者为4%。年龄≥65岁、靶体积≥5 cm³、最大剂量≥26 Gy及肿瘤进展与脑室扩大风险增加相关。

要点

  • SRS后非梗阻性脑室扩大发生率约3.6%,其中60.9%需分流。
  • 荟萃分析示SRS后脑积水总发生率5%,症状性需分流率4%。
  • 年龄≥65岁、靶体积≥5 cm³、最大剂量≥26 Gy及肿瘤进展增加脑室扩大风险。

核心结论

  • 约5%的前庭神经鞘瘤患者在接受初次SRS治疗后可能出现非梗阻性脑室扩大,但并非所有患者均出现症状或需要分流。
  • 高龄(≥65岁)、较大的肿瘤体积及SRS后肿瘤生长可能与交通性脑积水风险增加相关,或需更密切的临床监测。

主要发现

  • 本队列中,SRS后364例(57.4%)肿瘤缩小,218例(34.4%)肿瘤大小无变化,52例(8.2%)肿瘤生长。
  • 23例(3.6%)出现非梗阻性脑室扩大,其中9例(39.1%)无症状,14例(60.9%)需放置脑室腹腔分流,中位分流时间为8个月。
  • 多因素分析显示,年龄≥65岁(p=0.038)、SRS靶体积≥5 cm³(p<0.001)、最大SRS剂量≥26 Gy(p=0.015)及最近随访时肿瘤生长(p=0.002)与SRS后脑室扩大风险增加相关。
  • 症状性交通性脑积水需分流与年龄较大(p=0.049)、SRS靶体积增加(p=0.002)及肿瘤生长(p=0.016)相关。
  • 荟萃分析中,汇总7825例患者的SRS后脑积水总体发生率为5%;对7081例患者的亚组分析显示,症状性脑积水需分流的发生率为4%,而出现SRS后脑室扩大的患者总体分流率为92%。

关键数值与推荐

  • 本队列中非梗阻性脑室扩大发生率为3.6%(23/634)。
  • 荟萃分析中SRS后脑积水总体发生率为5%(7825例),症状性脑积水需分流发生率为4%(7081例)。
  • 出现SRS后脑室扩大的患者中,总体分流率为92%。
  • 多因素分析中与脑室扩大风险增加相关的因素:年龄≥65岁(p=0.038)、SRS靶体积≥5 cm³(p<0.001)、最大SRS剂量≥26 Gy(p=0.015)、肿瘤生长(p=0.002)。
  • 与症状性脑积水需分流风险增加相关的因素:年龄较大(p=0.049)、SRS靶体积增加(p=0.002)、肿瘤生长(p=0.016)。

临床怎么用

  • 对年龄≥65岁、肿瘤体积较大或SRS后肿瘤生长的前庭神经鞘瘤患者,应考虑更密切的临床和影像学监测以早期发现脑室扩大。
  • SRS后出现脑室扩大的患者中多数可能需分流,应关注症状性交通性脑积水的发生并及时评估分流指征。

局限性

  • 本研究为单中心回顾性队列研究,可能存在选择偏倚和回顾性数据固有的局限性。
  • 荟萃分析纳入的研究间存在异质性,且部分研究可能为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Communicating hydrocephalus may occur following stereotactic radiosurgery (SRS) for vestibular schwannomas (VSs), yet identifying individual patient risk factors associated with this post-SRS complication remains a challenge. This study examined predictors of nonobstructive ventricular enlargement and symptomatic communicating hydrocephalus following primary SRS treatment for VS via a single-center institutional cohort review and meta-analysis of the literature. METHODS: A retrospective single-institution cohort study and systematic literature review and meta-analysis examining post-SRS communicating hydrocephalus in VS was performed. RESULTS: The institutional cohort consisted of 634 patients who received primary SRS as treatment for VS. The cohort was 51.6% female, with a median age of 64 (range 18-89) years. Following SRS treatment, 364 patients (57.4%) experienced tumor shrinkage, 218 (34.4%) had no change in the size of their lesion, and 52 (8.2%) experienced tumor growth. Nonobstructive ventricular enlargement was observed in 23 patients (3.6%) following SRS treatment, of whom 9 (39.1%) remained asymptomatic and 14 (60.9%) required placement of a ventriculoperitoneal (VP) shunt, with a median time to shunt placement of 8 months. In the multivariate analysis, patients ≥ 65 years old (p = 0.038), SRS target volume ≥ 5 cm3 (p < 0.001), maximum SRS dose ≥ 26 Gy (p = 0.015), and tumor growth at the most recent follow-up (p = 0.002) were associated with an increased risk of post-SRS ventricular enlargement. Similarly, patients with older age (p = 0.049), increased SRS target volume (p = 0.002), and tumor growth (p = 0.016) were at an increased risk of symptomatic communicating hydrocephalus requiring VP shunt placement. Twenty-nine studies, including the cohort in this study, met inclusion criteria in the meta-analysis. Of the pooled 7825 patients, the overall incidence of hydrocephalus following SRS was 5%, and a subanalysis of 7081 patients demonstrated the incidence of symptomatic hydrocephalus requiring a VP shunt to be 4%. In this subanalysis, the overall shunting rate in patients who experienced post-SRS ventriculomegaly was 92%. Among individual studies in the literature, increased tumor size was most commonly found to be a statistically significant risk factor for post-SRS hydrocephalus. CONCLUSIONS: Approximately 5% of patients may experience nonobstructive ventricular enlargement following primary SRS treatment for VS. However, not all patients may be symptomatic and require shunting. Patients who are older (≥ 65 years), those with larger tumor volumes, and those with post-SRS tumor growth may be at increased risk of communicating hydrocephalus and may benefit from closer clinical monitoring.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Bauman MMJ, Bouchal SM, Morshed RA, et al. Risks associated with ventriculomegaly and symptomatic communicating hydrocephalus following stereotactic radiosurgery for vestibular schwannoma. J Neurosurg. 2026. PMID: 42066355. doi:10.3171/2025.12.JNS25176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。